What is the principal advantage of Olinvyk, a newly approved opioid pain reliever, over available other opioid analgesics?
b. Less chance of abuse
c. no dosage adjustments in patients with renal impairment
d. does not cause fatal respiratory depression
e. more patient compliance due to its oral dosage form
Answer: (c). Olinvyk is an opioid agonist that is the first new chemical entity in this IV drug class in decades and offers a differentiated profile that addresses a significant unmet need in the acute pain management landscape. Olinvyk delivers IV opioid efficacy with a rapid 2-5 minute onset of action. In addition, Olinvyk requires no dosage adjustments in patients with renal impairment, a large patient population with significant medical complications.
"Complex patients present unique challenges in the management of their postoperative acute pain, due to the presence of medical comorbidities that can complicate dosing," said Gregory Hammer, M.D., Professor of Anesthesiology, Perioperative and Pain Medicine, and of Pediatrics at Stanford University. "Olinvyk represents a new alternative for clinicians, due to its rapid onset of action, effective pain relief, and unique profile."
The active ingredient found in Olinvyk is Oliceridine. It is available in injection dosage form. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Olinvyk for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:
1. Have not been tolerated, or are not expected to be tolerated
2. Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
The cumulative total daily dose should not exceed 27 mg.
1. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
2. Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.
3. Initiate treatment with a 1.5 mg dose.
4. For patient controlled analgesia (PCA), recommended demand dose is 0.35 mg, with a 6-minute lock-out. A demand dose of 0.5 mg may be considered.
Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation or following a dose increase.
Concomitant use of Olinvyk with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
Concomitant use with Serotonergic Drugs may result in serotonin syndrome. Discontinue Olinvyk if serotonin syndrome is suspected.
Nausea, vomiting, dizziness, headache and hypotension are reported side effects of the drug.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.